drugset
drugset / Trial / NCT01008852

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

NCT01008852 ↗

Phase 2 Completed 210 enrolled Pfizer Emergent Product Development Seattle LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.

Timeline

Start
2009-12
Primary completion
2011-09
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SBI-087 Protein / enzyme biologic 200 mg Subcutaneous
Background Methotrexate Small molecule — —

Indications

rheumatoid arthritis